ASCO24: Akeso's bispecific vvonescimab faces a rocky road ahead in NSCLC

While commercial uptake may be difficult for ivonescimab, a positive regulatory decision would help validate Akeso's bispecific platform.

Related Keywords

United States ,China ,American ,Chinese ,Astrazeneca Tagrisso ,Williamn William Jr ,Akeso Tetrabody ,Astrazeneca ,Johnson ,American Society Of Clinical Oncology ,American Society ,Clinical Oncology ,Summit Therapeutics ,North America Exclusive ,Pharmaceutical Technology ,